Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling

Journal of Infection and Chemotherapy

Volumn 9, Issue 4, 2003, Pages 292-296

  Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobials; Monte Carlo analysis; Pharmacodynamics; Telithromycin

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTIBUTEN; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DAPTOMYCIN; GATIFLOXACIN; KETOLIDE; LEVOFLOXACIN; LINEZOLID; LORACARBEF; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; ERADICATION THERAPY; HOST PATHOGEN INTERACTION; HUMAN; IN VITRO STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; OUTCOMES RESEARCH; PROBABILITY; REACTION OPTIMIZATION; REVIEW; SIMULATION; TIME; TREATMENT OUTCOME;

EID: 0346102551     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-003-0279-x     Document Type: Review

References (33)

1. Nicolau DP. Optimizing antimicrobial therapy and emerging pathogens. Am J Man Care 1998;4(10 (Suppl 2)):525-30.
2. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:151-7.
3. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45:3468-73.
4. Nicolau DP, Ambrose PG. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Am J Med 2001;111(Suppl 9A):13S-18S; discussion 36S-38S.
5. Drusano GL, Preston SL, Gotfried MH, Danziger LH, Rodvold KA. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2002;46:586-9.
6. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health System Pharmacy 2003:60:565-8.
7. Craig WA. Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
8. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacrodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(Suppl 3):38-44.
9. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rational for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
10. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-9.
11. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001;14:165-72.
12. Drusano G, Labro MT, Cars O, Mendes P, Shah P, Sorgel F, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect 1998;4(Suppl 2):S27-S41.
13. Vesga O, Bonnat C, Craig WA. In vivo pharmacodynamic activity of HMR 3647, a new ketolide (abstract). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada; 1997.
14. Moore RD, Lietman PS. Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
15. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-9.
16. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
17. Andes DR, Craig WA. In vivo pharmacodynamic activity of gatifloxacin against multiple bacterial pathogens (abstract). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999.
18. Lacy MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintiliani R, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-7.
19. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999;43:79-86.
20. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000:45:437-46.
21. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al. Antibacterial spectrum of a novel desfluoro(6) quinolone. BMS-284756. Antimicrob Agents Chemother 2000;44:3351-6.
22. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcas pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001:45:2793-7.
23. Mattoes HM, Banevicius M, Li D, Turley C, Xuan D, Nightingale CH, et al. Pharmacodynamic assessment of gatifloxacin against Streptococcas pneumoniae. Antimicrob Agents Chemother 2001;45:2092-7.
24. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinetics 1995;28:143-60.
25. Grant EM, Nicolau DP. Pharmacodynamic considerations in the selection of antibiotics for respiratory tract infections: Focus on the fluoroquinolones. Antibiotics for Clinicians 1999;3(Suppl 1):21-8.
26. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
27. Nicolau DP, Onyeji CO, Zhong M, Tessier PR, Banevicius MA, Nightingale CH. Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations. Antimicrob Agents Chemother 2000;44:1291-5.
28. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003:23:988-91.
29. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979;67:608-16.
30. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. J Pharmacother 2002;22:471-83.
31. Appelbaum PC, Hoellman DB, Hryniewicz W, Drukalska L, Hupkova H. Antipneumococcal activity of telithromycin against 294 pneumococci from ten central and eastern European Countries (abstract). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000.
32. Drusano GL, Preston SL. Utility of an 800-mg dose of telithromycin for CAP caused by extracellular pathogens: a preliminary assessment by pharmacodynamic modeling and Monte Carlo simulation (abstract). Clin Microbiol Infect 2002;8(Suppl 1):319.
33. Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31-40.